This HTML5 document contains 79 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01065/identifier/pubchem-substance/
n20http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n10http://linked.opendata.cz/resource/drugbank/company/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01065/identifier/drugbank/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01065/identifier/iuphar/
n22http://linked.opendata.cz/resource/drugbank/mixture/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01065/identifier/guide-to-pharmacology/
n27http://www.drugs.com/
n6http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB01065/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB01065/identifier/chebi/
n28http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n24http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n19http://linked.opendata.cz/ontology/mesh/
n29http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/
n3http://linked.opendata.cz/ontology/drugbank/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01065/identifier/pharmgkb/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01065/identifier/wikipedia/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01065/identifier/pdb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01065/identifier/kegg-compound/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01065/identifier/bindingdb/
n30http://linked.opendata.cz/ontology/sukl/drug/
n31http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01065/identifier/pubchem-compound/

Statements

Subject Item
n2:DB01065
rdf:type
n3:Drug
n3:description
Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers.
n3:generalReferences
# Boutin JA, Audinot V, Ferry G, Delagrange P: Molecular tools to study melatonin pathways and actions. Trends Pharmacol Sci. 2005 Aug;26(8):412-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15992934 # Caniato R, Filippini R, Piovan A, Puricelli L, Borsarini A, Cappelletti EM: Melatonin in plants. Adv Exp Med Biol. 2003;527:593-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15206778 # Hardeland R: Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine. 2005 Jul;27(2):119-30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16217125 # Hattori A, Migitaka H, Iigo M, Itoh M, Yamamoto K, Ohtani-Kaneko R, Hara M, Suzuki T, Reiter RJ: Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates. Biochem Mol Biol Int. 1995 Mar;35(3):627-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7773197 # Ma X, Chen C, Krausz KW, Idle JR, Gonzalez FJ: A metabolomic perspective of melatonin metabolism in the mouse. Endocrinology. 2008 Apr;149(4):1869-79. Epub 2008 Jan 10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18187545 # Reiter RJ, Acuna-Castroviejo D, Tan DX, Burkhardt S: Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann N Y Acad Sci. 2001 Jun;939:200-15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11462772
n3:group
approved nutraceutical
n3:halfLife
35 to 50 minutes
n3:indication
Used orally for jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind (evidence for efficacy), and benzodiazepine and nicotine withdrawal. Evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults. It has received FDA orphan drug status as an oral medication for this use. A number of studies have shown that melatonin may be effective for treating sleep-wake cycle disturbances in children and adolescents with mental retardation, autism, and other central nervous system disorders. It appears to decrease the time to fall asleep in children with developmental disabilities, such as cerebral palsy, autism, and mental retardation. It may also improve secondary insomnia associated with various sleep-wake cycle disturbances. Other possible uses for which there is some evidence for include: benzodiazepine withdrawal, cluster headache, delayed sleep phase syndrome (DSPS), primary insomnia, jet lag, nicotine withdrawal, preoperative anxiety and sedation, prostate cancer, solid tumors (when combined with IL-2 therapy in certain cancers), sunburn prevention (topical use), tardive dyskinesia, thrombocytopenia associated with cancer, chemotherapy and other disorders.
owl:sameAs
n6:DB01065 n28:DB01065
dcterms:title
Melatonin
adms:identifier
n8:9019 n9:16796 n11:ML1 n12:896 n13:1357 n14:C01598 n15:1357 n16:872 n17:Melatonin n18:DB01065 n21:PA164752558 n23:46509101
n3:mechanismOfAction
Melatonin is a derivative of tryptophan. It binds to melatonin receptor type 1A, which then acts on adenylate cylcase and the inhibition of a cAMP signal transduction pathway. Melatonin not only inhibits adenylate cyclase, but it also activates phosphilpase C. This potentiates the release of arachidonate. By binding to melatonin receptors 1 and 2, the downstream signallling cascades have various effects in the body. The melatonin receptors are G protein-coupled receptors and are expressed in various tissues of the body. There are two subtypes of the receptor in humans, melatonin receptor 1 (MT1) and melatonin receptor 2 (MT2). Melatonin and melatonin receptor agonists, on market or in clinical trials, all bind to and activate both receptor types.The binding of the agonists to the receptors has been investigated for over two decades or since 1986. It is somewhat known, but still not fully understood. When melatonin receptor agonists bind to and activate their receptors it causes numerous physiological processes. MT1 receptors are expressed in many regions of the central nervous system (CNS): suprachiasmatic nucleus of the hypothalamus (SNC), hippocampus, substantia nigra, cerebellum, central dopaminergic pathways, ventral tegmental area and nucleus accumbens. MT1 is also expressed in the retina, ovary, testis, mammary gland, coronary circulation and aorta, gallbladder, liver, kidney, skin and the immune system. MT2 receptors are expressed mainly in the CNS, also in the lung, cardiac, coronary and aortic tissue, myometrium and granulosa cells, immune cells, duodenum and adipocytes. The binding of melatonin to melatonin receptors activates a few signaling pathways. MT1 receptor activation inhibits the adenylyl cyclase and its inhibition causes a rippling effect of non activation; starting with decreasing formation of cyclic adenosine monophosphate (cAMP), and then progressing to less protein kinase A (PKA) activity, which in turn hinders the phosphorilation of cAMP responsive element-binding protein (CREB binding protein) into P-CREB. MT1 receptors also activate phospholipase C (PLC), affect ion channels and regulate ion flux inside the cell. The binding of melatonin to MT2 receptors inhibits adenylyl cyclase which decreases the formation of cAMP.[4] As well it hinders guanylyl cyclase and therefore the forming of cyclic guanosine monophosphate (cGMP). Binding to MT2 receptors probably affects PLC which increases protein kinase C (PKC) activity. Activation of the receptor can lead to ion flux inside the cell.
n3:packager
n10:271B5DCD-363D-11E5-9242-09173F13E4C5 n10:271B5DCE-363D-11E5-9242-09173F13E4C5 n10:271B5DCC-363D-11E5-9242-09173F13E4C5 n10:271B5DCF-363D-11E5-9242-09173F13E4C5 n10:271B5DD0-363D-11E5-9242-09173F13E4C5
n3:synonym
N-Acetyl-5-methoxytryptamine Melatonine 5-methoxy-N-acetyltryptamine Melatonin N-[2-(5-methoxyindol-3-yl)ethyl]acetamide
n3:toxicity
<p>Generally well-tolerated when taken orally. The most common side effects, day-time drowsiness, headache and dizziness, appear to occur at the same frequency as with placebo. Other reported side effects include transient depressive symptoms, mild tremor, mild anxiety, abdominal cramps, irritability, reduced alertness, confusion, nausea, vomiting, and hypotension. Safety in Adults: Evidence indicates that it is likely safe to use in oral and parenteral forms for up to two months when used appropriately. Some evidence indicates that it can be safely used orally for up to 9 months in some patients. It is also likely safe to use topically when used appropriately. Safety in Children: Melatonin appeared to be used safely in small numbers of children enrolled in short-term clinical trials. However, concerns regarding safety in children have arisen based on their developmental state. Compared to adults over 20 years of age, people under 20 produce high levels of melatonin. Melatonin levels are inversely related to gonadal development and it is thought that exogenous administration of melatonin may adversely affect gonadal development. Safety during Pregnancy: High doses of melatonin administered orally or parenterally may inhibit ovulation. Not advised for use in individuals who are pregnant or trying to become pregnant. Safety during Lactation: Not recommended as safety has not be established.</p> <p>Oral, rat: LD<sub>50</sub> &ge;3200 mg/kg</p>
n3:mixture
n22:271B5DCB-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
n/a
n3:synthesisReference
Robert A. S. Welch, Keith Betteridge, "Method of stimulating cashmere growth on cashmere-producing goats using melatonin." U.S. Patent US4855313, issued August, 1986.
n19:hasConcept
n20:M0013319
foaf:page
n27:melatonin.html n29:mel_0286.shtml
n3:IUPAC-Name
n4:271B5DDB-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5DE1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5DE0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5DDD-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5DDE-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5DDF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5DD9-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5DDA-363D-11E5-9242-09173F13E4C5 n4:271B5DF2-363D-11E5-9242-09173F13E4C5 n4:271B5DD7-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5DD8-363D-11E5-9242-09173F13E4C5
n30:hasATCCode
n31:N05CH01
n3:H-Bond-Acceptor-Count
n4:271B5DE7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5DE8-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5DE2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5DE3-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5DE5-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5DE4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5DE6-363D-11E5-9242-09173F13E4C5
n3:absorption
The absorption and bioavailability of melatonin varies widely.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
73-31-4
n3:category
n3:containedIn
n24:271B5DD5-363D-11E5-9242-09173F13E4C5 n24:271B5DD6-363D-11E5-9242-09173F13E4C5 n24:271B5DD3-363D-11E5-9242-09173F13E4C5 n24:271B5DD4-363D-11E5-9242-09173F13E4C5 n24:271B5DD2-363D-11E5-9242-09173F13E4C5 n24:271B5DD1-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5DED-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5DEF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5DF0-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5DF1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5DEC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5DEB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5DEE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5DDC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5DE9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5DEA-363D-11E5-9242-09173F13E4C5